Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.58 - $19.77
Previous CloseN/A
Volume14.25K
Average Volume (3M)309.81K
Market Cap
$382.93M
Enterprise Value$424.07M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding37,839,394
10 Day Avg. Volume196,237
30 Day Avg. Volume309,808
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.96
Forecast
1Y Price Target
$30.00Price Target Upside194.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Celcuity News
PremiumCompany Announcements
Celcuity Inc. Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Celcuity Inc. Reports 2024 Financial Results and Clinical Updates---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Phase III VIKTORIA-1 trial is enrolling patients with a relatively healthier profile compared to previous trials, allowing for a potentially more favorable treatment outcome.
Financial StabilityCelcuity ended the fourth quarter with $235 million, supporting operations through 2026.
Regulatory ProgressGedatolisib has a breakthrough designation, leading to frequent interactions with the FDA.
Bears Say
Financial PerformanceThe company reported no revenues and a net loss of $1.10 per diluted share for 4Q24, compared to consensus estimate of no revenues and a net loss of $0.71 per diluted share.
Market SentimentShort interest in the stock is relatively high at 15% of the float.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.40% Insiders
11.74% Mutual Funds
0.65% Other Institutional Investors
48.94% Public Companies and
Individual Investors
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $7.58 and its highest was $19.77 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $382.93M.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is May 14, 2025 which is in 6 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Mar 31, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.862 by $0.012.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celcuity have?
Celcuity has 37,839,394 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.862. Following the earnings report the stock price went down -8.111%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
---
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (194.70% Upside)
$30.00 (194.70% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 803.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.27%
12-Months-Change
Fundamentals
Return on Equity
-87.54%
Trailing 12-Months
Asset Growth
28.19%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
---
CELC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical development programs and strong financial positioning, offset by increased net loss and expenses. The promising clinical data and potential for blockbuster revenue suggest a positive outlook.Read More>---
CELC Stock 12 Month Forecast
Average Price Target
$30.00
▲(194.70% Upside)
Technical Analysis
Altimmune
―
Autolus Therapeutics
―
Oric Pharmaceuticals
―
Abivax SA Sponsored ADR
―
Rapport Therapeutics, Inc.
―
---